

SUPPLEMENTARY FIG. S2. Original images of cropped Western blots. (A) Western blot representing the efficiency of different concentrations of MAO-A siRNA (i.e., 20–40–60 pmol) compared with scramble (Scr) in NRVMs. The image refers to Supplementary Figure S1B. (B) Western blot representing the expression level of MAO-A in NRVMs treated with or without 0.5 μ M doxorubicin for 24 h. The image refers to Supplementary Figure S1F. (C) Western blot representing the expression level of MAO-B in AMVMs treated with or without 0.5 μ M doxorubicin for 24 h. The image refers to Supplementary Figure S1G. (D) Western blot representing LC3B-II abundance in isolated NRVMs treated with 0.5 μ M doxorubicin for 24 h, in the presence or absence of 100 μ M pargyline. The image refers to Supplementary Figure S3D. (E) Western blot representing p62 expression levels in isolated NRVMs treated with 0.5 μ M doxorubicin for 24 h, in the presence or absence of 100 μ M pargyline. The image refers to Supplementary Figure S3E.